Drugs / BD311
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05099094 | Nov 2021 → Nov 2024 | diabetic macular edema, retinal vein occlusion, wet macular degeneration | Shanghai BDgene Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BD311 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05099094 ↗ |
| Action | Inhibit | “neutralizes the VEGFA activity” NCT05099094 ↗ |
| Route | Other | “Administered by suprachoroidal injection.” NCT05099094 ↗ |
| Target | VEGFA | “express the VEGFA antibody which neutralizes the VEGFA activity” NCT05099094 ↗ |